Moderna announces the latest developments

October 13, 2023

Moderna announces the latest developments

January 16, 2018 Source: WuXi PharmaTech

Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];

Last year, Moderna's strong financing capabilities (nearly $2 billion) were impressive. Now, Moderna is ready to inject synthetic mRNA, a modified mRNA, into the patient's body, allowing the patient's cells to produce the drug themselves. At the recently held JP Morgan Healthcare Conference, Moderna Therapeutics released the company's latest developments.

The company's first phase 2a trial is a new drug, mRNA-AZD8601, targeting vascular endothelial growth factor (VEGF-A), which will work with AstraZeneca.

A new drug candidate, mRNA-3927, has been published for a rare disease of propionateemia (PA).

A new research drug (IND) application for KRAS cancer vaccine mRNA-5671 was submitted.

Two phase 1 preventions against mRNA-1647 (a cytomegalovirus (CMV) vaccine) and mRNA-1653 (human metapneumovirus and parainfluenza virus type 3 combination vaccine) Sexual vaccine research.

A new drug candidate, mRNA-1944, was released, which enables the liver to express antibodies, potentially neutralizing the chikungunya virus in the blood; and a prophylactic vaccine against the chikungunya virus infection. Phase 1 clinical trial of -1388.

â–² Mr. Stephane Bancel, CEO of the company (Source: Moderna official website)

“We are proud of the progress made in the past year as we continue to see the pipeline development momentum and productivity of our platform and continue to validate the progress of mRNA science,” said company CEO Stephane Bancel: “We have achieved research and development. Key milestones, from the four clinical projects at the beginning of this year to the present, 10 drugs have entered the human research phase, and our goal is to continue to advance our product line quickly through a series of new development projects."

â–² Mr. John Mendlein, President of Corporate and Product Strategy (Source: Moderna official website)

In addition, Moderna also announced that John Mendlein will join the company as president of corporate and product strategy. Mendlein is the founder and vice chairman of the board of Fate Therapeutics. He also serves on the board of directors of Editas Medicine and Axcella Health. For the past six years, he has served as CEO of aTyr Pharma.

The addition of new executives indicates that Moderna may strengthen its own portfolio of research and development pipeline projects through strategic cooperation to accelerate the production of individualized cancer vaccines and other products to maintain its leading position in the mRNA field.

Mandlein said: "I have worked with companies that have excellent platforms and science. Moderna's science is very powerful and the range of applications is very broad."

Reference materials:

[1] Biotech Unicorn Moderna Details Game Plan, Reveals Infectious Disease Programs

Fertility Tests

In vitro diagnosis of fertility mainly includes the following three categories:
1. HCG Pregnancy Test is a rapid chromatographic immunoassay for the qualitative detection of human chorionic gonadotropin in urine or serum to aid in the early detection of pregnancy.

2.The One Step LH Urine Ovulation Test is fast and easy to use. It is a qualitative test that can predict when there is a LH (luteinizing hormone) surge, and in turn, when you are likely to ovulate.

3.One Step FSH Menopause Test is a rapid, one-step, visual test for the qualitative detection of follicle stimulating hormone (FSH) in human urine. It is to be used as a confirmation of body hormone changes related to the symptoms associated with the changes of menopause and as an adjunctive screen of fertility for home use by women who are attempting to conceive but have been unsuccessful.

Precaution
1. For in vitro diagnostic use only
2. This reagent is designed for the qualitative screening test. A confirmed pregnancy diagnosis should
be made only by a physician after all clinical and laboratory findings have been evaluated.
3. Do not use test kit beyond expiry date.
4. The test device should not be reused.
5. Do not use other kinds of quality control sample to test the reagent. Components of different
batches cannot be exchanged for use to avoid erroneous results

Fertility Tests,Early Pregnancy Hcg Test,Lh Ovulation Test,Fsh Menopause Test

Changchun ZYF science and technology CO.,LTD , https://www.zyf-medical.com

Back to top